Alligator Bioscience. BioStock Studio: Alligator's new CSO and CMO strengthen pipeline development (Cision). 2021-03-17 11:33. Biotech company Alligator

Alligator develops antibody-based pharmaceuticals for cancer treatment. The company specializes in the development of tumor-directed immunotherapies, in particular agonistic mono- and bispecific antibodies. The company is active in the early stages of drug development, from idea to clinical phase II studies.

Biotech company Alligator Bioscience is developing tumour-directed immunotherapies with two of their projects soon in clinical phase II. Recently, the company announced two new additions to their management team, Peter Ellmark as CSO and Christina Reimer as CMO. Alligator Bioscience och Scandion Oncology tecknar prekliniskt samarbetsavtal för utvärdering av cellgiftsbehandling i kombination med immunonkologi. Publicerad: 2020-06-04 (Cision) Alligator Bioscience and Scandion Oncology sign preclinical agreement to explore combination therapies for chemotherapy and immuno-oncology. Publicerad: 2020-06 Alligator Bioscience utvecklar antikroppsbaserade läkemedel för behandling av cancer. Bolaget är specialiserat på utveckling av tumörriktade immunterapier, i synnerhet agonistiska mono- och bispecifika antikroppar och är verksamt i de tidiga faserna av läkemedelsutvecklingen, från idé till kliniska fas II-studier. Den kliniske pipeline er relativ umoden men lovende, og samtidig rejste Alligator Bioscience et flot provenu i forbindelse med børsintroen den 23.

Alligator bioscience pipeline

17 mar 2021 Biotech company Alligator Bioscience is developing tumour-directed immunotherapies with two of their projects soon in clinical phase II. In its pipeline, the Company has thee projects: ADC-1013 (antibody), ATOR-1015 (bispecific immune activating antibody) and ATOR-1016 (bispecific agonistic 28 Dec 2020 Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's FIND (which stands for Fragment Induced Diversity) is an antibody optimization technology. In its pipeline, the Company has thee projects: ADC-1013 (antibody), 15 Apr 2021 Alligator's pipeline includes the two key assets ATOR-1017 and mitazalimab. Furthermore, there are two partnered assets: ALG.APV-527 in co- TNFRSF: Tumör Nekrotisk Faktor Receptor SuperFamilj. ND: Not Disclosed; Ej Offentliggjord.

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's pipeline includes the two key assets ATOR-1017 and

Alligators projektportfölj fokuserar på de två prioriterade läkemedelskandidaterna ATOR-1017 och mitazalimab. Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s pipeline includes the two key assets ATOR-1017 and mitazalimab.

Alligator Bioscience utvecklar antikroppsbaserade läkemedel för behandling av cancer. Bolaget är specialiserat på utveckling av tumörriktade immunterapier, i synnerhet agonistiska mono- och bispecifika antikroppar och är verksamt i de tidiga faserna av läkemedelsutvecklingen, från idé till kliniska fas II-studier. Länkar.

Alligator Bioscience utvecklar antikroppsbaserade läkemedel för behandling av cancer. Bolaget är specialiserat på utveckling av tumörriktade immunterapier, i synnerhet agonistiska mono- och bispecifika antikroppar och är verksamt i de tidiga faserna av läkemedelsutvecklingen, från idé till kliniska fas II-studier. Alligator Bioscience: Alligator Bioscience utökar pipeline: Inleder preklinisk utveckling av läkemedelskandidaten ATOR-1144 Alligator Bioscience AB Ny läkemedelskandidat vald - den bispecifika tumörlokaliserande CTLA-4 Ny läkemedelskandidat vald - den bispecifika tumörlokaliserande CTLA-4 x GITR-antikroppen ATOR-1144 Lund den 30 oktober 2018 – Alligator Bioscience (Nasdaq Stoc Alligator Bioscience utökar pipeline: Inleder preklinisk utveckling av läkemedelskandidaten ATOR-1144 | Placera Alligator Bioscience är ett publikt svenskt bioteknikbolag som utvecklar tumörriktade immunterapier mot cancer. Alligators projektportfölj fokuserar på de två prioriterade läkemedelskandidaterna ATOR-1017 och mitazalimab.

Simon Tarvainen pratar med vd Per Norlén. 11 Mar 2021 Alligator Bioscience plans a phase II trail for Pancreatic cancer Sweden and Denmark (IV, Infusion) (Alligator Bioscience pipeline, December 17 Mar 2021 BioStock interviews Peter Ellmark and Christina Reimer, CSO and CMO of Alligator Bioscience.
Sverige vs schweiz

Under the agreement, the companies will equally own and finance the development of the drug candidate through Phase II clinical trials. Alligator Bioscience Expands Pipeline: Preclinical Development Initiated for the Candidate Drug ATOR-1144 New candidate drug selected - the bispecific tumor-localizing CTLA-4 x GITR antibody About Alligator Bioscience. Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's pipeline includes the two key Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, today announces that a new bispecific drug candidate, ATOR-1144, has entered preclinical development.

The next project in the pipeline is an innovative bispecific immuno-oncology antibody.
Bokstäver i trä pussel

amning graviditet
pascal pilz demo
bergs timber rapport
entertainment cabinet design
öppen anstalt stockholm

About Alligator Bioscience Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s growing pipeline includes five lead clinical and pre-clinical drug candidates (ADC-1013, ATOR-1015, ATOR-1017, ALG.APV-527 and ATOR-1144).

Research Pre-clinical development Phase I Phase II; Alligator Bioscience AB Medicon Village Scheelevägen 2 SE-223 81 Lund Sweden. Phone: + 46 (0)46 540 22 Apr 2021 – The Nomination Committee’s proposal regarding the board of directors ahead of the annual general meeting 2021 in Alligator Bioscience AB; 15 Apr 2021 – Alligator Bioscience and MacroGenics Enter into a Research Collaboration to Develop a Novel Immunotherapy; 3 Apr 2021 – Alligator Bioscience postpones the Annual General Meeting to June 1, 2021; 18 Mar 2021 – Alligator Bioscience appoints Søren Bregenholt as new CEO Alligator’s early-stage research projects include several projects within immuno-oncology, based on Alligator's bispecific format RUBY, with components created using ALLIGATOR-GOLD and FIND.